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INFLAMMATORY GENE EXPRESSION IN WOMEN DIAGNOSED WITH
POLYCYSTIC OVARIAN SYNDROME

An Abstract of the Thesis by
Myles K Taylor

Polycystic ovarian syndrome (PCOS) is a common endocrine disorder in women
of reproductive age. The pathophysiology of PCOS has conventionally thought to
originate from androgen excess. However, recent evidence suggests that androgen excess
is a downstream consequence to inflammatory dysregulation and subsequent metabolic
abnormalities. Inflammatory mRNA gene expression of TNF and IL-1ß in mononuclear
cells isolated from women diagnosed with PCOS was explored using qPCR. Also, the
correlations between body mass index (BMI) and fasting glucose on mRNA expression
of TNF and IL-1ß were explored. mRNA expression of both TNF and IL-1ß were
found to be significantly higher in PCOS subjects (P<0.01). BMI was found to
significantly increase mRNA expression of TNF and IL-1ß (P<0.05). However, only
mRNA expression of TNF was found to correlate with fasting glucose (P<0.05).
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CHAPTER I

INTRODUCTION

Polycystic Ovarian Syndrome
Polycystic ovarian syndrome (PCOS), first identified in 1935 by Dr. Stein and
Leventhal, is a common endocrine disorder affecting women of childbearing years [1].
Approximately 4 to 7 percent of women are affected. Women affected by PCOS are more
likely to receive care for heart disease, diabetes, and mental health conditions. $4.36
billion dollars are spent annually on the care for women with PCOS [2]. Currently, the
etiology of PCOS is poorly understood. However, recent literature has suggested
inflammatory dysregulation in mononuclear cells (MNC) plays a significant role in the
early stages of PCOS.
Clinical manifestations associated with PCOS are very broad and are not limited
gynecological issues. Diagnosis of PCOS is highly disputed among medical professions
due to several similarities with other pathologies. No single definitive diagnostic test
exists for PCOS, rather, a collective of physical and biochemical signs is considered for
diagnosis. Rotterdam criteria (Table 1) are the most commonly used guidelines for
diagnosis of PCOS [3-5]. Obesity and insulin resistance, although not considered
diagnostic criterion of PCOS, are highly prevalent among women with PCOS, and
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contribute long-term health risks such as cardiovascular disease, type 2 diabetes, and
dyslipidemia [3, 4, 6].

Rotterdam Criteria 2003
1. Oligo-and/or anovulation
2. Clinical and/or biochemical signs of hyperandrogenism
3. Polycystic ovaries
(Two of three criteria needed)
Table 1. Rotterdam Criteria 2003

The majority of physical manifestations experienced in PCOS are the result of
excess androgen hormones. Hair follicles and sebaceous glands are androgen-dependent
structures and are commonly affected by the increased androgens in PCOS leading to
hirsutism, pattern baldness, and acne [5, 7].
PCOS represents a complex pathophysiological model with no single causative
agent currently determined. Rather, multiple factors contributing to the signature
biochemical feature of hyperandrogenism. Excess androgens are the main culprit behind
the majority of clinical features of PCOS [5].
Several abnormalities in ovarian physiology occur in women with PCOS. AntiMüllerian hormone (AMH) is secreted by granulosa cells (GC) and plays a significant
role in folliculogenesis. AMH is commonly elevated in PCOS and arrests the progression
towards ovulation through inhibition of primodial follicle initiation and sensitivity to
follicle-stimulating hormone (FSH) [8]. Poor fertility outcomes are in women with PCOS
due to ovulation inhibition. Chronic absence of ovulation encourages the continual
endometrial stimulation by estrogen, increasing the risk of endometrial hyperplasia and
endometrial cancer [6, 9].
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Abnormalities in hypothalamus-hypophysis-ovary axis feedback resulting in
greater secretion of luteinizing hormone (LH) is another common feature of PCOS.
Elevated LH stimulates ovarian theca cells (TC) to over synthesize androgens resulting in
hyperandrogenism. Hypoandrogenism decreases the feedback inhibition of progesterone
and estradiol leading to greater secretion of LH. Disturbances in feedback mechanisms
perpetuates a pathophysiological cycle of hyperandrogenism [5, 10].
Although hyperandrogenism is the culprit for the majority of the clinical
manifestations in PCOS, the primary pathophysiological changes in PCOS are poorly
understood. Insulin resistance may play an important upstream role in androgen
dysregulation. In normal populations, insulin resistance is most commonly associated
with obesity related inflammation. While the majority of women with PCOS are
classified as obese, a small portion have normal body compositions in addition to insulin
resistance. Therefore, obesity is most likely not the primary cause of insulin resistance.
Recent literature has suggested that inflammatory dysregulation in MNCs independent of
body composition contributes to insulin resistance in PCOS [11, 12].

Body Composition and Inflammation
Obesity poses a significant public health risk with nearly 80 million people
affected in the United States. Approximately 69% of adults are overweight with 35%
classified as obese. Significant increases in developing chronic diseases such as type 2
diabetes mellitus, hypertension, and chronic heart disease are associated with obesity.
Clinical guidelines identify obese individuals as a body mass index 30 kg/m2 [13, 14].
The majority of women diagnosed with PCOS have elevated BMI with approximately
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70% classified as obese. However, there remains a small portion of women with PCOS
who fall within a normal BMI range [15, 16]. Obesity is well defined as a significant
inflammatory stimulus and contributor to the development of insulin-resistance and type
2 diabetes. However, the role of obesity in the pathogenesis of PCOS remains unknown.
Despite this, it is likely that when obesity is present with PCOS, reproduction, and
metabolic aberrations are more prevalent [17].
Unlike the common features of swelling, redness and pain found in an acute
inflammatory response due to tissue injury, obesity-related inflammation is derived from
metabolic stimuli and maintained at subacute levels. Substantial differences in
adipocytokine expression exist between adipose tissue from lean and obese individuals.
Adipose tissue from obese individuals expressed greater amounts of inflammatory TNF
and IL-1ß. TNF and IL-1ß are major contributors to the development of glucose
intolerance and insulin resistance, as well as atherosclerosis [18-20]. Conversely, tissue
from normal weight individuals expressed greater amounts of cytokines of antiinflammatory nature, such as IL-4 [21, 22]. Adipocytokines heavily mediate immune and
inflammatory responses through epigenetic modifications of hematopoietic cells [23, 24].
Macrophage, derived from monocytes, are the potent mediators of inflammation
through the secretion of cytokines. Two major phenotypes of macrophages exist,
inflammatory M1 phenotype and anti-inflammatory M2 phenotype. Though, this view is
simplistic. Depending on the signaling environment, individual macrophage exhibit
various degrees of inflammatory and anti-inflammatory nature, and must be sustained in
a similar environment to exhibit that phenotype. In obese individuals, increased
expression of inflammatory cytokines in adipose tissue promotes the M1 phenotype.
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Consequently, a shift towards the M1 phenotype increases the inflammatory environment
through the increased production of inflammatory cytokines. Whereas, adipose tissue
from lean individuals expresses an anti-inflammatory environment, shifting towards the
M2 phenotype. By producing cytokines of anti-inflammatory nature, M2 macrophage
maintain an anti-inflammatory environment [25-29]. Interestingly, M1 and M2
macrophage phenotypes have different preferred energy substrates. Glucose is the
primary substrate used by M1 macrophages. M2 macrophage prefers fatty acids as an
energy substrate. Also, macrophages primarily use insulin-independent glucose
transporters despite having a functional insulin receptor. Insulin-independent glucose
uptake becomes interesting when insulin resistance and hyperglycemia are present, and
uptake and utilization of glucose remain normal in macrophage [25, 30-32].

Inflammation and Insulin Resistance
Inflammation is well understood to be a major contributor to the development of
insulin resistance in insulin-sensitive tissues. Cytokines are capable of acting in an
endocrine fashion if secreted into the blood stream. As obesity increases and subsequent
cytokine production increases, inflammatory mediators can enter the blood stream and
travel to peripheral tissues leading to insulin resistance within insulin sensitive tissues. Of
particular interest, the cardinal inflammatory cytokine TNF has been shown to directly
inhibit proper insulin signaling through interactions with insulin receptor substrate-1
(IRS-1). Binding of TNF to the TNF receptor leads the activation of JNK and IKK and
subsequent phosphorylation of IRS-1 serine residues. Consequently, the IRS-1 function is
decreased, decreasing the activation of phosphoinositide 3-kinase (PI3K) [33-35].
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Decreased activity of PI3K results in the inhibition of protein kinase B (Akt2), which is
responsible for the translocation of the insulin-dependent glucose transporter GLUT-4.
Under normal insulin signaling, Akt leads to the suppression of gluconeogenesis through
inhibition of FoxO1. When abnormal signaling occurs, and Akt activation decreases,
FoxO1 functions normally and gluconeogenesis continues. Consequently, plasma glucose
begins to rise as gluconeogenesis continues and remains at hyperglycemic concentrations
due to the decreased uptake of glucose into the cell by GLUT-4 [36].
Maintaining a hyperglycemic state has several consequences to various tissues.
Most notably are the destruction of pancreatic ß-cells which are responsible for the
production of insulin. As a compensatory mechanism, hyperglycemia stimuli signal ßcells to increase the production and secretion of insulin. If this is allowed to continue, ßcells will eventually die, leading to type 2 diabetes mellitus and the necessity of
supplying exogenous insulin.
Hyperglycemia also contributes to promoting an inflammatory state through the
preferred bioenergetic pathway of M1-like macrophages. Despite the presence of insulinresistance, uptake of glucose by M1-like macrophages is maintained through insulinindependent transporters and used as an energy substrate in mitochondrial respiration.
Reactive oxygen species is a strong signal for transcription of inflammatory mediators
and is primarily produce from NAPDH oxidase during mitochondrial respiration.
Consequently, another source of inflammation is added and contributes to the cyclical
nature of inflammation and insulin resistance [37].
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Insulin and Hyperandrogenism
Insulin, in addition to glucose homeostasis, regulates GnRH and LH secretion
from the pituitary and transcription of the androgen synthesizing enzymes in the ovaries.
While insulin resistance and hyperinsulinemia develops in peripheral tissues, the pituitary
and ovaries remain highly sensitive to insulin in PCOS. Increased LH secretion
consequently augments steroid synthesis in the ovaries. In the ovaries, physiological
doses of insulin are capable of inducing synthesis of androgens though increase acute
steroidogenic regulatory protein (StAR) in women with PCOS. Much larger doses of
insulin are required to elicit the same response in normal women [38-40]. Insulin also
increases the activity of 17--hydroxylase/17,20-lyase, 3-ß-hydroxysteroid
dehydrogenase, and aromatase leading to excess production of progesterone, 17-hydroxyprogesterone, and testosterone [5, 41].

Body Composition-Independent Inflammation in PCOS
Obesity is a significant promoter of inflammation and insulin-resistance.
However, recent studies show that women with PCOS demonstrate elevated
inflammatory markers and insulin resistance independent of obesity. Compared to BMImatched controls, women with PCOS have higher circulating levels of TNF and IL-1ß.
However, when obesity is present with PCOS, these cytokines are elevated to a greater
degree [11, 12, 42]. Distribution and physiology of adipose tissue may provide an
explanation for increased inflammatory markers and insulin resistance in normal weight
women with PCOS. A large DXA population study found that women with PCOS
preferentially store visceral adipose in the abdominal region, leading to increased android
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adiposity in normal weight women. Increased android fat mass in normal weight women
with PCOS positively correlated with serum insulin and androgens [15, 43]. However,
increased android adiposity cannot explain insulin resistance and increased inflammation
in all PCOS cases, particularly lean women.
Insulin resistance and increased inflammation in the absence of excess adiposity
is found in lean women with PCOS, suggesting inflammation is not originally derived
from adipose tissue. Rather, evidence suggests that the inflammatory response is nutrientinduced. Mononuclear cells (MNC) were isolated from lean and obese women with
PCOS and their matching controls during a glucose tolerance test. IL-6, TNF, and IL-1ß
were assayed from MNC after culturing for 24hr. MNC from both lean and obese women
with PCOS were found to secrete greater amounts of IL-6, TNF and IL-1ß compared to
their counterparts. The similar inflammatory response was observed when challenged
with lipids rather than glucose [11, 12, 44].
Utilizing glucose tolerance testing provides a practical in vivo model simulating
daily nutrient intake. However, the inflammatory cytokines were assayed from cell
culture supernatant after culturing for 24hr. Assaying cytokines in this ex vivo fashion
does not completely represent the inflammatory response of the individual. Also, only
secreted cytokines were assayed, and does not take into account intracellular cytokines.
Although, the observed increase in cytokine production among PCOS groups compared
to normal controls indicates inflammatory dysregulation.
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Current Therapies
Due to poor understanding of underlying pathogenesis, therapeutic options are
limited for PCOS. Treatment is often limited to lifestyle modifications, insulin sensitizing
agents, and oral contraceptives. Diet and exercise for weight loss are the first choice for
overweight and obese individuals. However, diet and exercise as a monotherapy has very
limited efficacy. Metformin, commonly used for type 2 diabetes, is used to treat insulin
resistance in PCOS. Yet, long-term efficacy is poor [45]. Contraceptives containing
estrogen and progestin derivatives are commonly prescribed to treat symptoms of excess
androgens. However, use of hormonal contraceptives come with several unwanted side
effects, including limiting the ability to conceive [6].

Purpose of this Research
Polycystic ovarian syndrome represents a complex pathophysiological model of
cyclical nature. Poor understanding of PCOS pathophysiology has greatly limited
therapies available to clinicians. Previous work exploring inflammatory cytokine
expression in PCOS have been limited to post translation analysis The objective of this
study is to evaluate transcriptional mRNA expression of inflammatory cytokines TNF
and IL-1ß and their correlation to metabolic disturbances in women with PCOS.
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CHAPTER II

MATERIALS AND METHODS

Subjects
Thirty-nine women, 25 with PCOS (5 non-obese, 20 obese) and 14 without PCOS
(9 non-obese, 5 obese), 18-55 years of age volunteered for this study. Non-obese and
obese were defined as having a BMI of <30 and >30 kg/m2, respectively. Subjects were
enrolled through the medical practice of Patricia Sullivan, NP-C. All study subjects were
screened using Rotterdam criteria. PCOS subjects were selected by meeting two of the
criteria in Table 1. Control subjects had normal ovulation and did not exhibit physical
manifestations of excess androgens. Subjects taking medications for metabolic conditions
were excluded from the study. The Pittsburg State University Institutional Review Board
provided approval for the study. Informed consent was obtained from all participants
prior to sample collection.

Body Composition
Height and body weight were recorded with a height rod and beam scale. Height
was measured to the nearest 1.0 in and body weight was measured to the nearest 1.0 lb.
Body mass index was calculated from measured height and weight.
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Biochemical Analysis
After a 12 hour overnight fast, 24 mL of blood was obtained from an antecubital
vein to measure serum glucose and to isolate MNCs. Twenty mL of blood was treated
with K2 EDTA to prevent coagulation for isolation of MNCs. The remaining 4 mL of
blood was allowed to clot and centrifuged at 1,000 x g for 10 minutes to remove the clot.
Fasting serum glucose was determined by hexokinase G-6-PDH methodology (Mag Lab
Medical Laboratory, Pittsburg, KS). MNC relative gene expression of TNF and Il1ß
was determined by quantitative polymerase chain reaction (qPCR) and SYBR green
chemistry.

Mononuclear Cell Isolation
Immediately after collection, uncoagulated blood samples were diluted with an
equal volume of phosphate buffered saline (PBS), inverted several times to mix
thoroughly. Diluted blood was then carefully layered upon Lymphoprep density gradient
media and centrifuged at 10˚C for 30 minutes at 800 x g with the brake off. The buffy
coat containing mononuclear cells was collected and washed with PBS. Mononuclear
cells were pelleted at 10˚C for 10 minutes at 1200 x g. The PBS supernatant was removed
and the remaining cell pellet was lysed in 1 mL of TRI-Reagent BD (MRC) and
transferred to a 1.7 mL microfuge tube.

RNA Isolation
Before isolating RNA, benchtop and pippettors were thoroughly cleaned and
treated with RNase Away (Ambion). Phase separation was performed by adding 200 µL
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of chloroform, mixed vigorously by hand for 15 seconds and centrifuged at 4˚C for 15
minutes at 12,000 x g. 400 µL of the RNA containing aqueous layer was removed and
transferred to a new 1.7 microfuge tube. An equal volume of 99% ethanol was added to
the aqueous layer and transferred to a Direct-Zol (Zymo Research) RNA isolation
column. All centrifugation steps were performed at 12,000 x g. The column was
centrifuged for 30 seconds, discarding the flow through. 400 µL of RNA wash was added
to the column and centrifuged for 30 seconds, discarding the flow though. The column
was transferred to a new collection tube. An on column DNA digest was performed to
remove residual gDNA with DNase I for 15 minutes. 400 µL of preRNA wash was added
to the column and centrifuged for 30 seconds, discarding the flow. This step was
performed for a second time. 700 µL of RNA wash was added and centrifuged for 1 min.
The Direct-zol column was then transferred to a microfuge tube. 50 µL of nuclease free
water was added to the column matrix and incubated for 1 minute and centrifuged for 1
minute. RNA concentration and purity was quantified with a NanoDrop lite analyzer.
Isolated total RNA was stored at -80˚C.
RNA integrity was determined by gel electrophoresis right before cDNA
synthesis. Five µL of isolated total RNA was heated to 95˚C for 1 min and immediately
put on ice. A 1.2% agarose gel was made by heating 0.6 g of agarose in 50 mL of 1x
TAE buffer. 2 µL of ethidium bromide was added to the mixture. The solution was then
poured into a casting tray to solidify. After solidifying, the agarose gel was transferred to
an electrophoresis chamber and the chamber was filled with 1x TAE buffer until covering
the top of the agarose gel. Five µL of 6x loading dye was added to each RNA sample and
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loaded into the agarose gel. Electrophoresis was performed at 90V for 30 minutes. The
gel was then imaged on a FluroChem E under UV light.

cDNA Synthesis
cDNA was synthesized from 2 µg of isolated total RNA using SuperScript IV
VILO master mix (Invitogen). SuperScript IV VILO contains a mixture of oligo-dT and
random hexamers. 4 µL of SuperScript IV VILO master mix, variable volume of
template RNA for 2 µg of total RNA, and variable volume of nuclease free H2O to bring
the final volume to 20 µL. Reaction was thoroughly mixed by pipetting. Thermal cycling
condition were 25˚C for 10 minutes, 50˚C for 10 minutes, and 85˚C for 5 minutes.
Synthesized cDNA was diluted with nuclease free water to obtain a concentration of 10
ng/µL and separated in several aliquots to prevent multiple freeze thaw cycles. Diluted
cDNA samples were stored at -20˚C.

Primer Design and Kinetics Validation
Primers for TNF, IL-1ß, TBP, and SDHA were selected based on product size,
exon spanning, and primer annealing temperatures above 60˚C. Selected primer
sequences were analyzed by Primer-Blast (NCBI) for specificity and amplicon size.
Sequences and product sizes are shown in Table 2. Primers were synthesized by
Integrated DNA Technologies and supplied in 100 nmol stock concentration. Several
aliquots of 10 pmol primer solution were prepared by 1:10 dilution of the 100 nmol stock
solution to prevent freeze/thaw degradation of primers. Primers were stored at -20˚.
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Target
TNF

IL-1ß
TBP

SDHA

Product Size
Forward

5’-CCTGCCCCAATCCCTTTATT-3’

Reverse

5’-CCCTAAGCCCCCAATTCTCT-3’

Forward

5’-ATGATGGCTTATTACAGTGGCAA-3’

Reverse

5’-GTCGGAGATTCGTAGCTGGA-3’

Forward

5’-TGCACAGGAGCCAAGAGTGAA-3’

Reverse

5’-CACATCACAGCTCCCCACCA-3’

Forward

5’-TGGGAACAAGAGGGCATCTG-3’

Reverse

5’-CCACCACTGCATCAAATTCATG-3’

81 bp

132 bp
132 bp

86 bp

Table 2. Forward and Reverse Primer Sequence and Product Size

A gBlock® Gene Fragment (Integrative DNA Technologies) containing each
PCR amplicon was synthesized and diluted to 100 pg/mL to serve as a positive control,
reference sample, and inter-run calibrator. Several aliquots of the synthetic DNA
template were made to prevent multiple freeze/thaw cycles and stored at -20˚C. Kinetic
efficiencies for each PCR assay was determined from a sevenfold dilution series of the
synthetic DNA template. The first concentration of the dilution series was 100 pg/mL.
Several 1:10 dilutions were made until a final concentration of 0.0001 pg/mL. In a clean
biosafety cabinet, PCR reactions were prepared by combining 10 µL of PowerUp SYBR
Green master mix (Invitrogen), 0.4 µL of 10 pmol forward primer, 0.4 µL of 10 µL
reverse primer, 7.2 µL of nuclease free H2O, and 2 µL of template for a final reaction
volume of 20 µL. A no template control was prepared by replacing template DNA with
nuclease free H2O. PCR reactions were prepared in triplicate, pipetted into a 48 well
qPCR optical plate, and sealed with optical adhesive film. Reaction plates were
centrifuged at 500 x g for 1 minute to collect reaction mixture and remove bubbles
formed from pipetting. qPCR was performed using an Applied Biosystems StepOne
qPCR machine. Thermal cycling conditions were 50˚C for 2 minutes to activate UDG,
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95˚C for 2 minutes for initial DNA denaturation, followed by 40 cycles of 95˚C for 3
seconds and an annealing/extension temperature of 60˚C for 30 seconds. SYBR green
fluoresces was measured after each annealing/extension step. A dissociation melting
curve was included after the last annealing/extension step. Baseline and threshold Cq
settings were determined by the Applied Biosystems native software. Reaction replicates
were averaged and plotted against the log10 of template input. Kinetic efficiencies were
calculated from the slope of the trend line using eq 1 [46].

Efficiency = 10(-1/slope) (eq. 1)

After performing a dissociation melting curve, the PCR product was
electrophoresed on a 3% agarose gel to ensure one product and absence of primer dimer
formation. 1.5 g of agarose was heated in 50 mL of 1x TAE buffer until boiling. 2 µL of
ethidium bromide was added and poured into a casting tray to cool. After solidifying, the
agarose gel was transferred to an electrophoresis chamber and covered in 1x TAE buffer.
5 µL of 6x loading dye was added to each PCR reaction and loaded into the agarose gel.
Electrophoresis was performed at 60V for 90 minutes. After electrophoresis, the agarose
gel was imaged on an FluroChemE under UV light.

Quantitative PCR
After assay efficiency was determined, qPCR was performed on cDNA samples
derived from subject MNCs to determine relative expression of TNF and IL-1ß using
TBP and SDHA as reference genes to normalize cDNA input. One target was run per
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PCR run to maximize plate efficiency and conserve reagents. Using the synthetic
template as a reference sample, positive control, and inter-run calibrator, inter-run
variance can be accounted for and targets on separate runs can be compared.
In a clean biosafety cabinet, PCR reactions prepared by combining 10 µL of
PowerUp SYBR green master mix, 0.4 µL of forward primer, 0.4 µL of reverse primer,
7.2 µL of H2O, and 2 µL of sample template for a final volume of 20 µL. A no template
control was included on each plate. Each reaction was prepared in triplicate, pipetted into
the 48 well qPCR optical plate, and sealed with optical adhesive film. qPCR optical
plates were centrifuged at 500 x g for 1 min to collect reaction and remove bubbles
introduced from pipetting. qPCR was performed using an Applied Biosystems StepOne
qPCR machine. Thermal cycling conditions were 50˚C for 2 minutes to activate UDG,
95˚C for 2 minutes for initial DNA denaturation, followed by 40 cycles of 95˚C for 3
seconds and an annealing/extension temperature of 60˚C for 30 seconds. SYBR green
fluoresces was measured after each annealing/extension step. A dissociation melting
curve was included after the last annealing/extension step. Baseline and threshold Cq
settings were adjusted to Cq threshold determined from primer validation.

Reference Gene Stability and Relative Gene Expression
Cq data across fourteen experiments were uploaded into qBase+ 3.0 (Biogazelle)
to determine reference gene stability and relative gene expression of TNF and IL-1ß.
Sample replicates with Cq variance of  0.5 were excluded from data analysis. TBP and
SDHA were used to normalize variance in cDNA input. Assay PCR kinetic efficiencies
were included in data calculation to account for variation in efficiencies.
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Statistics
Data were analyzed by SPSS Statistics (IBM Analytics). Relative gene expression
data was log transformed to meet normality requirements. One-Way ANOVA was used
to compare relative gene expression between women with PCOS and control women
followed by LSD post hoc to compare subgroups. Correlation analysis was performed by
single and multiple linear regression. Significance was accepted as P  0.05.
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CHAPTER III

RESULTS

Age, BMI, and Fasting Glucose
Subjects age, height, weight, and BMI (Appendix 1) were obtained prior to
collecting sample collection. Fasting glucose (Appendix 1) values and peripheral
mononuclear cells were obtained after fasting 12 hours prior. BMI was significantly
(P0.001) different between obese and non-obese subjects regardless of PCOS (Table 3).
Fasting glucose was similar among all subjects. Age was significantly (P0.001)
different among all subjects.

Age (y)
BMI (kg/m)
Glucose (mg/dL)

PCOS
Non-Obese
Obese
(n=5)
(n=20)
40±14
31±7
26±3
43±6
90±3
95±16

Control
Non-Obese
(n=9)
19±2
25±2
89±6

Obese
(n=5)
24±8
39±8
90±2

Table 3. Age, Body Composition, and Fasting Glucose of Subjects. Values are
expressed as means ± SD.

Isolated Total RNA Purity and Integrity
Total RNA from peripheral mononuclear cells was isolated using phenolchloroform phase separation and silica spin column methodology. A NanoDrop Lite
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spectrophotometer was used to quantify total RNA concentration and purity. Protein
contamination was minimal with 260/280 nm ratios between 1.8 and 2.0 for all samples.
Intact 16s and 28s rRNA bands were observed for all samples after separation by
electrophoresis on a 1.2% agarose gel (Figure 1), indicating minimally degraded RNA
prior to cDNA synthesis.

Figure 1. 1.2% RNA Gel Electrophoresis

Primer kinetic efficiencies
Replicate Cq values for each dilution were averaged and plotted against the log10
value of the input DNA amount (Figure 2). PCR kinetic efficiencies (Table 4) were
calculated from the slope of the trend line using eq 1. All assays fell between 86-93%
efficiency. Linearity (R20.999) was observed for each assay across the dilution series
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indicating PCR inhibitors were minimal. Dissociation curve analysis (Figure 3) revealed
a single melting peak for each assay representing a single PCR product. Gel
electrophoresis (Figure 4) further indicated a single PCR product and the absence of
primer dimer formation.

a

b

c
d
Figure 2. Correlation of Cq and DNA Input Amount a, TNF R20.999 b, IL-1ß
R2=1.000 c, R2=1.000 d, R2=1.000
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Efficiency
1.86
1.89
1.86
1.93

TNF
IL-1ß
TBP
SDHA
Table 4. Assay PCR Kinetic Efficiency

a

b

c
d
Figure 3. Dissociation Curve. a, TNF b, IL-1ß c. TBP d. SDHA

21

Figure 4. 3% Agarose Gel Electrophoresis of PCR Product

geNorm and qBase+
qPCR data across fourteen experiments was uploaded to qBase+. Two sample
replicates out of 176 were removed for exceeding variance cutoff of >0.5 Cq. Relative
gene expression of TNF and IL-1ß was quantified by normalizing to reference genes
TBP and SDHA (Table 5). geNorm analysis (CV=0.198) indicates stability of both
reference genes across all samples.

Sample
A1
A2
A3
A4
A5
A6
A7
A8
A9
A10
A11
A12

TNFa RQ
0.46
0.63
0.49
0.63
0.45
0.57
0.66
0.74
0.36
0.30
0.38
0.38

IL-1ß RQ
1.62
0.63
0.68
1.22
0.49
1.19
0.89
0.82
0.92
0.95
1.40
0.75

Sample
A21
A22
A23
A24
A25
B1
B2
B3
B4
B5
B6
B7
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TNFa RQ
0.56
0.45
0.59
0.65
0.87
0.41
0.62
0.37
0.41
0.57
0.34
0.40

IL-1ß RQ
2.86
1.72
1.29
1.33
1.12
1.01
0.90
0.76
0.52
0.48
0.62
0.80

0.87
1.48
A13
B8
0.62
0.77
A14
B9
0.34
0.70
A15
B10
0.32
0.80
A16
B11
0.55
1.52
A17
B12
0.51
1.06
A18
B13
0.44
0.84
A19
B14
0.39
1.00
A20
Table 5. Relative quantity of TNF and IL-1ß.

0.38
0.42
0.34
0.26
0.26
0.27
0.31

0.74
0.86
0.59
0.97
1.01
0.67
0.99

MNC-derived TNF and IL-1ß expression
An analysis of variance showed that the effect of PCOS on TNF and IL-1ß
expression was significant, F(1,37) = 10.866, P=0.002 and F(1,37) = 7.588, P=0.009
respectively (Figure 5). A post hoc LSD test (Figure 6) showed a significant (P=0.003)
difference between non-obese controls and obese PCOS, non-obese PCOS and obese
controls were not significantly different from the other groups.

a
b
Figure 5. Mononuclear Cell Cytokine Expression. Relative quantity of a, TNF and b,
IL-1ß from fasting samples. Significantly greater expression of TNF (P=0.002) and IL1ß (P=0.009) in women with PCOS compared to women without PCOS.
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a
b
Figure 6. Mononuclear Cell Cytokine Expression. Relative quantity of a, TNF and b,
IL-1ß from fasting samples. Expression of IL-1ß is significantly different between nonobese controls and obese PCOS (P=0.003).

A simple linear regression was calculated to predict TNF and IL-1ß expression
based on BMI for all study subjects. A significant regression equation was found (F(1,38)
= 12.004, P=0.001), with an R2=0.240 and (F(1,38) = 5.681, P=0.022), with an R2=0.122
respectively.

a
b
Figure 7. Correlation Between BMI and Cytokine Expression. a, TNF (P=0.001) b,
IL-1ß (P=0.022).
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A simple linear regression was calculated to predict TNF and IL-1ß expression
based on BMI among women with PCOS. An insignificant regression equation was
found (F(1,24) = 3.464, P=0.075), with an R2=0.126 for TNF and (F(1,24) = 2.881,
P=0.101), with an R2=0.096 for IL-1ß.

a
b
Figure 8. Correlation between BMI of women with PCOS and cytokine expression.
a, TNF expression (P=0.075) and b, IL1ß expression (P=0.101).

A simple linear regression was calculated to predict TNF and IL-1ß expression
based on fasting glucose for all study subjects. A significant regression equation was
found (F(1,37) = 5.214, P=0.028), with an R2=0.124. An insignificant regression
equation was found (F(1,37) = 2.798, P=0.102), with and R2=0.065 for IL-1ß.
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a
b
Figure 9. Correlation between fasting glucose and cytokine expression. a, TNF
expression (P=0.028) and b, IL-1ß expression (P=0.102).

A simple linear regression was calculated to predict TNF and IL-1ß expression
based on fasting glucose for PCOS subjects. An insignificant regression equation was
found (F(1,24) = 2.328, P=0.141, with an R2=0.092 for TNF and (F(1,24) = 1.625,
P=0.214), with and R2=0.059 for IL-1ß.

a
b
Figure 10. Correlation between fasting glucose of women with PCOS and Cytokine
Expression a, TNF (P=0.141) b, IL-1ß (P=0.214).
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Multiple linear regression analysis was calculated to predict TNF and IL-1ß
expression based on BMI and fasting glucose among women with PCOS. An
insignificant regression was found (F(2,22) = 2.329, P=0.121) for TNF, and R2=0.175,
and (F(2,22) = 1.682, P=0.206), and R2=0.119 for IL-1ß. BMI and fasting glucose were
not found to be significant predictors of TNF and IL-1ß in women with PCOS.
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CHAPTER IV

DISCUSSION

Polycystic ovarian syndrome is a common endocrine disorder in women of
reproductive age and represents a complex pathophysiological model. Traditionally,
PCOS has been characterized by the presence of excess androgens. However, excess
androgens may be a secondary consequence of abnormal metabolic physiology. Obesity,
a highly prevalent morbidity in women with PCOS, is well understood to contribute to an
inflammatory environment leading to the development of insulin resistance. Although, a
portion of women with PCOS remain who exhibit insulin resistance in the absence of
obesity. Insulin resistance in the absence of obesity suggests an alternative mechanism
mediating insulin sensitivity in women with PCOS. Recent evidence has suggested that
that inflammatory dysregulation is a primary mediator leading to insulin resistance.
Subsequent metabolic abnormalities resulting from impaired insulin sensitivity drives the
clinical manifestation of excess androgens.
The effect of adiposity and fasting glucose on mRNA expression of TNF and
IL-1ß in MNCs was explored in women diagnosed with PCOS. Overexpression of both
TNF and IL-1ß are widely known to contribute to the development of glucose
intolerance, insulin resistance, and atherosclerosis [18-20]. Data from this study gives
evidence that mRNA expression of both TNF and IL-1ß are increased in PCOS and
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remains consistent with previous literature assaying protein. TNF and IL-1ß mRNA was
found to positively correlate with BMI in all study subjects, suggesting that BMI is a
significant contributor of inflammation. However, a significant increase in TNF and IL1ß mRNA was not observed when only comparing PCOS subjects. Limitations in sample
size may contribute to this observation. Although, BMI does not account for the
distribution of adipose tissue in the individual. Preferential android adipose distribution
may potentially contribute to the increased inflammatory environment observed in PCOS.
Correlations between fasting glucose and mRNA expression of TNF and IL-1ß
were also explored. Fasting glucose was observed to have little impact on TNF and IL-ß
mRNA expression in PCOS. However, a positive correlation was found between fasting
glucose and TNF among all study subjects. Plasma glucose concentration is heavily
dependent on insulin concentration, and may inaccurately represent glycemic status by
lowering plasma glucose if insulin is elevated. An improved model of glycemic status,
homeostatic model assessment of insulin resistance (HOMA-IR), accounts for both
glucose and insulin concentration.
Increased mRNA expression of TNF and IL-1ß gives evidence that an
inflammatory phenotype is predominant in PCOS. Inflammatory signals promote and
maintain differentiation of macrophage towards the M1 phenotype. Maintaining an
inflammatory environment significantly contributes to the development of insulin
resistance and subsequent metabolic aberrations observed in PCOS.
Further research exploring inflammatory, and anti-inflammatory expression when
challenged with a glucose load during a 3˚ glucose tolerance test may provide greater
insight to the correlation between metabolic aberrations and inflammatory cytokine
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expression. Inclusion of plasma insulin would provide a greater representation of
glycemic status and insulin resistance of the subject. Also, measuring waist to hip
circumference in addition to BMI may be a more significant indicator of adiposity than
BMI alone.
In summary, this study provides evidence that mRNA expression of TNF and
IL-1ß is increased in women with PCOS. Therefore, inflammation is a significant
pathophysiological component in PCOS that potentially plays a critical role in developing
insulin resistance and hyperandrogenism.
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APPENDIX

Sample

Age (y)

BMI (kg/m2)

Glucose (mg/dL)

A1

30

51.3

119

A2

32

38.4

92

A3

39

36.1

92

A4

37

47.5

123

A5

33

31.3

90

A6

26

44.6

82

A7

33

40.5

135

A8

37

38.8

94

A9

29

36.4

72

A10

19

25.0

92

A11

47

42.7

94

A12

40

29.8

94

A13

26

46.1

112

A14

28

49.4

88

A15

21

38.9

87

A16

35

43.1

87

A17

48

27.3

89

A18

24

40.6

83

A19

22

46.1

84

A20

22

36.2

99

A21

33

47.3

99

A22

36

21.8

86

A23

42

51.4

90

A24

55

26.4

89

A25

21

48.0

84

B1

39

49.8

90

B2

25

28.3

91

B3

18

22.6

81

B4

20

30.0

90

B5

23

42.4

93

B6

18

25.5

84

B7

18

22.3

78

B8

18

41.2

90

B9

18

26.5

82

B10

18

21.3

97

B11

18

31.9

87

B12

18

26.7

90

35

B13

20

25.1

87

B14

18

26.6

87

Appendix 1. Age, BMI, and fasting glucose
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